-
-
-
-
-
-
-
Beam Therapeutics (BEAM) to Sell Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease to Eli Lilly for Up to $600M
-
-
-
-
-
-
-
Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results
-
-
-
-
-
-
-
Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base Editing to the Liver and Other Tissues
-
-
-
-
-
-
-
Beam Therapeutics Reports Business Updates and Full Year 2019 Financial Results
-
-
-
-
-
-
-
Unusual 11 Mid-Day Movers 01/13: (RNN) (ALNY) (TSH) Higher; (GSE) (SODA) (ICPT) Lower
-
-
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

